ELVN

Enliven Therapeutics, Inc.

Price Chart

Latest Quote

$45.10

+0.24 (+0.54%)

Current Price

Previous Close	$44.86
Open	$45.01
Day High	$45.72
Day Low	$44.22
Volume	2,449,816

Fetched: 2026-06-22T00:20:38

Stock Information

Shares Outstanding	69.84M
Total Debt	$302K
Cash Equivalents	$452.40M
Net Income	$-98.78M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$3.15B
EPS (TTM)	$-1.64
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$2.29B
Income	$-98.78M
Book/sh	$7.45
Cash/sh	$6.48
Employees	61

Financial Ratios

Quick Ratio	39.38
Current Ratio	40.32
Debt/Eq	0.07

Returns & Margins

ROA	-18.86%
ROE	-26.64%

Ownership

Insider Ownership	6.55%
Institutional Ownership	90.99%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-18.56
P/B	6.06

Analyst Data

Recommendation	strong_buy
Target Price	$60.11

Technical Indicators

SMA20	$39.77
SMA50	$41.75
SMA200	$28.23
RSI	60.65
ATR	3.4001

Shares Float	44.72M
Short Float	13.55%
Short Ratio	8.29
Volatility	0.40
Rel Volume	1.42

Performance History

Week	+11.74%
Month	+12.27%
Quarter	+50.08%
6 Months	+166.71%
YTD	+190.22%
Year	+106.88%
3 Years	+120.00%
5 Years	+31.87%
10 Years	-24.83%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$45.10	2,449,800
2026-06-17	$44.86	1,505,500
2026-06-16	$42.55	3,453,900
2026-06-15	$42.36	2,790,500
2026-06-12	$46.13	6,145,900
2026-06-11	$40.36	5,099,600
2026-06-10	$37.00	1,271,800
2026-06-09	$36.11	1,834,800
2026-06-08	$33.63	834,000
2026-06-05	$34.71	1,076,300
2026-06-04	$35.49	1,126,900
2026-06-03	$36.03	696,200
2026-06-02	$35.52	1,810,200
2026-06-01	$37.51	694,800
2026-05-29	$39.57	747,900
2026-05-28	$40.65	303,300
2026-05-27	$41.41	519,000
2026-05-26	$42.53	538,900
2026-05-22	$41.54	631,900
2026-05-21	$42.25	918,300
2026-05-20	$41.86	638,500
2026-05-19	$40.17	636,100

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

📰 Latest News

Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial

Insider Monkey • 2026-06-13T07:02:23Z

ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development

Stocktwits • 2026-06-12T18:22:56Z

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of SpaceX Debut

MT Newswires • 2026-06-12T13:15:03Z

Enliven Therapeutics Reports Positive Phase 1 CML Data and FDA Alignment for Phase 3 Trial (ELVN)

InvestorsHub • 2026-06-11T14:36:13Z

Enliven Therapeutics Says Aligned With US FDA on Dose Recommendation for Late-Stage Chronic Myeloid Leukemia Trial

MT Newswires • 2026-06-11T13:11:19Z

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

BioPharma Dive • 2026-06-11T09:27:31Z

Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls

The Fly • 2026-06-09T13:32:55Z

A Look At Enliven Therapeutics (ELVN) Valuation As ENABLE Trial Data Update Nears

Simply Wall St. • 2026-06-07T21:19:50Z

Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.

Motley Fool • 2026-06-01T21:45:01Z

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter

Motley Fool • 2026-05-31T20:16:27Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$119,658,000	$104,554,000	$83,529,000	$38,791,000
Other Income Expense	$-49,000	$871,000	$-22,000	-
Other Non Operating Income Expenses	$-49,000	$-2,000	$-22,000	-
Net Non Operating Interest Income Expense	$16,013,000	$14,891,000	$11,967,000	$1,129,000
Operating Expense	$119,658,000	$104,554,000	$83,529,000	$38,791,000
General And Administrative Expense	$33,802,000	$23,776,000	$18,955,000	$7,769,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-103,694,000	$-89,024,000	$-71,584,000	$-37,662,000
Net Interest Income	$16,013,000	$14,891,000	$11,967,000	$1,129,000
Interest Income	$16,013,000	$14,891,000	$11,967,000	$1,129,000
Normalized Income	$-103,694,000	$-89,713,670	$-71,584,000	$-37,662,000
Net Income From Continuing And Discontinued Operation	$-103,694,000	$-89,024,000	$-71,584,000	$-37,662,000
Total Operating Income As Reported	$-119,658,000	$-104,554,000	$-83,529,000	$-38,791,000
Net Income Common Stockholders	$-103,694,000	$-89,024,000	$-71,584,000	$-37,662,000
Net Income	$-103,694,000	$-89,024,000	$-71,584,000	$-37,662,000
Net Income Including Noncontrolling Interests	$-103,694,000	$-89,024,000	$-71,584,000	$-37,662,000
Net Income Continuous Operations	$-103,694,000	$-89,024,000	$-71,584,000	$-37,662,000
Pretax Income	$-103,694,000	$-88,792,000	$-71,584,000	$-37,662,000
Special Income Charges	$0	$873,000	$0	-
Interest Income Non Operating	$16,013,000	$14,891,000	$11,967,000	$1,129,000
Operating Income	$-119,658,000	$-104,554,000	$-83,529,000	$-38,791,000
Per Share
Diluted EPS	$-1.83	$-1.89	$-2.01	$-0.92
Basic EPS	$-1.83	$-1.89	$-2.01	$-0.92
Other
Tax Effect Of Unusual Items	$0	$183,330	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-119,395,000	$-105,110,000	$-83,232,000	$-38,576,000
Total Unusual Items	$0	$873,000	$0	-
Total Unusual Items Excluding Goodwill	$0	$873,000	$0	-
Reconciled Depreciation	$263,000	$317,000	$297,000	$215,000
EBITDA (Bullshit earnings)	$-119,395,000	$-104,237,000	$-83,232,000	$-38,576,000
EBIT	$-119,658,000	$-104,554,000	$-83,529,000	$-38,791,000
Diluted Average Shares	$56,664,000	$47,073,000	$35,546,215	$41,100,000
Basic Average Shares	$56,664,000	$47,073,000	$35,546,215	$41,100,000
Diluted NI Availto Com Stockholders	$-103,694,000	$-89,024,000	$-71,584,000	$-37,662,000
Tax Provision	$0	$232,000	$0	-
Restructuring And Mergern Acquisition	$0	$-873,000	$0	-
Research And Development	$85,856,000	$80,778,000	$64,574,000	$31,022,000
Selling General And Administration	$33,802,000	$23,776,000	$18,955,000	$7,769,000
Other Gand A	$33,802,000	$23,776,000	$18,955,000	$7,769,000

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$459,600,000	$309,845,000	$245,906,000	$-76,825,000
Total Assets	$476,168,000	$325,760,000	$271,867,000	$83,298,000
Total Non Current Assets	$1,290,000	$7,633,000	$5,716,000	$5,545,000
Other Non Current Assets	$656,000	$7,175,000	$4,091,000	$54,000
Non Current Deferred Assets	$217,000	$0	$563,000	$3,975,000
Current Assets	$474,878,000	$318,127,000	$266,151,000	$77,753,000
Other Current Assets	$12,257,000	$4,633,000	$12,949,000	$2,217,000
Restricted Cash	$0	$54,000	$54,000	$0
Cash Cash Equivalents And Short Term Investments	$462,621,000	$313,440,000	$253,148,000	$75,536,000
Cash And Cash Equivalents	$98,896,000	$124,117,000	$100,141,000	$75,536,000
Debt
Total Debt	$399,000	$0	$335,000	$323,000
Current Debt And Capital Lease Obligation	$399,000	-	$335,000	$323,000
Liabilities
Total Liabilities Net Minority Interest	$16,568,000	$15,915,000	$25,961,000	$160,123,000
Total Non Current Liabilities Net Minority Interest	$0	$0	$67,000	$150,408,000
Current Liabilities	$16,568,000	$15,915,000	$25,894,000	$9,715,000
Other Current Liabilities	$351,000	$204,000	$10,364,000	$447,000
Payables And Accrued Expenses	$11,523,000	$11,102,000	$11,867,000	$6,815,000
Payables	$2,159,000	$1,342,000	$532,000	$3,438,000
Accounts Payable	$2,159,000	$1,342,000	$532,000	$3,438,000
Other Non Current Liabilities	-	-	$67,000	$659,000
Equity
Common Stock Equity	$459,600,000	$309,845,000	$245,906,000	$-76,825,000
Total Equity Gross Minority Interest	$459,600,000	$309,845,000	$245,906,000	$-76,825,000
Stockholders Equity	$459,600,000	$309,845,000	$245,906,000	$-76,825,000
Gains Losses Not Affecting Retained Earnings	$334,000	$55,000	$141,000	$0
Other Equity Adjustments	$334,000	$55,000	$141,000	-
Retained Earnings	$-347,166,000	$-243,472,000	$-154,448,000	$-82,864,000
Preferred Securities Outside Stock Equity	-	-	$0	$149,749,000
Other
Ordinary Shares Number	$59,440,045	$48,936,459	$41,292,027	$41,100,000
Share Issued	$59,440,045	$48,936,459	$41,292,027	$41,100,000
Tangible Book Value	$459,600,000	$309,845,000	$245,906,000	$-76,825,000
Invested Capital	$459,600,000	$309,845,000	$245,906,000	$-76,825,000
Working Capital	$458,310,000	$302,212,000	$240,257,000	$68,038,000
Capital Lease Obligations	$399,000	$0	$335,000	$323,000
Total Capitalization	$459,600,000	$309,845,000	$245,906,000	$-76,825,000
Additional Paid In Capital	$806,373,000	$553,213,000	$400,172,000	$6,038,000
Capital Stock	$59,000	$49,000	$41,000	$1,000
Common Stock	$59,000	$49,000	$41,000	$1,000
Preferred Stock	$0	$0	$0	$0
Current Capital Lease Obligation	$399,000	$0	$335,000	$323,000
Pensionand Other Post Retirement Benefit Plans Current	$4,295,000	$4,609,000	$3,328,000	$2,130,000
Current Accrued Expenses	$9,364,000	$9,760,000	$11,335,000	$3,377,000
Net PPE	$417,000	$458,000	$1,062,000	$1,516,000
Accumulated Depreciation	$-229,000	$-919,000	$-671,000	$-374,000
Gross PPE	$646,000	$1,377,000	$1,733,000	$1,890,000
Other Properties	$383,000	$1,113,000	$1,511,000	$1,817,000
Machinery Furniture Equipment	$263,000	$264,000	$222,000	$73,000
Other Short Term Investments	$363,725,000	$189,323,000	$153,007,000	$0

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-70,459,000	$-73,236,000	$-61,418,000	$-32,689,000
Operating Activities
Operating Cash Flow	$-70,301,000	$-73,192,000	$-61,269,000	$-32,077,000
Cash Flow From Continuing Operating Activities	$-70,301,000	$-73,192,000	$-61,269,000	$-32,077,000
Operating Gains Losses	$106,000	$11,000	-	-
Investing Activities
Capital Expenditure	$-158,000	$-44,000	$-149,000	$-612,000
Investing Cash Flow	$-173,841,000	$-35,997,000	$-148,412,000	$-612,000
Cash Flow From Continuing Investing Activities	$-173,841,000	$-35,997,000	$-148,412,000	$-612,000
Net Other Investing Changes	-	$873,000	-	-
Financing Activities
Issuance Of Capital Stock	$216,169,000	$128,883,000	$0	-
Financing Cash Flow	$218,867,000	$133,165,000	$234,286,000	$-1,799,000
Cash Flow From Continuing Financing Activities	$218,867,000	$133,165,000	$234,286,000	$-1,799,000
Net Other Financing Charges	$-217,000	-	$233,887,000	$-2,390,000
Net Common Stock Issuance	$216,169,000	$128,883,000	$0	-
Common Stock Issuance	$216,169,000	$128,883,000	$0	-
Repurchase Of Capital Stock	-	-	-	-
Net Preferred Stock Issuance	-	-	-	-
Other
Income Tax Paid Supplemental Data	$0	$232,000	$0	-
End Cash Position	$98,896,000	$124,171,000	$100,195,000	$75,590,000
Beginning Cash Position	$124,171,000	$100,195,000	$75,590,000	$110,078,000
Changes In Cash	$-25,275,000	$23,976,000	$24,605,000	$-34,488,000
Proceeds From Stock Option Exercised	$2,915,000	$4,282,000	$399,000	$591,000
Net Investment Purchase And Sale	$-173,896,000	$-36,826,000	$-148,263,000	$0
Sale Of Investment	$272,898,000	$313,914,000	$120,000,000	$0
Purchase Of Investment	$-446,794,000	$-350,740,000	$-268,263,000	$0
Net PPE Purchase And Sale	$55,000	$-44,000	$-149,000	$-612,000
Sale Of PPE	$213,000	$0	-	-
Purchase Of PPE	$-158,000	$-44,000	$-149,000	$-612,000
Change In Working Capital	$-1,121,000	$-4,541,000	$1,401,000	$438,000
Change In Other Current Liabilities	$-337,000	$-335,000	$-310,000	$4,000
Change In Payables And Accrued Expense	$321,000	$562,000	$5,414,000	$2,024,000
Change In Accrued Expense	$-496,000	$-248,000	$7,664,000	$1,613,000
Change In Payable	$817,000	$810,000	$-2,250,000	$411,000
Change In Account Payable	$817,000	$810,000	$-2,250,000	$411,000
Change In Prepaid Assets	$-1,105,000	$-4,768,000	$-3,703,000	$-1,590,000
Other Non Cash Items	$353,000	$-553,000	$306,000	-
Stock Based Compensation	$34,019,000	$20,174,000	$12,914,000	$3,191,000
Amortization Of Securities	$-227,000	$424,000	$-4,603,000	$0
Depreciation Amortization Depletion	$263,000	$317,000	$297,000	$215,000
Depreciation And Amortization	$263,000	$317,000	$297,000	$215,000
Depreciation	$263,000	$317,000	$297,000	$215,000
Gain Loss On Sale Of PPE	$106,000	$11,000	$0	-
Net Income From Continuing Operations	$-103,694,000	$-89,024,000	$-71,584,000	$-37,662,000
Asset Impairment Charge	-	-	$0	$1,741,000
Preferred Stock Payments	-	-	-	-
Change In Other Current Assets	-	-	-	-

Fetched: 2026-06-16